Increasing prevalence of extended-spectrum-betalactamase among Gram-negative bacilli in Latin America – 2008 update from the Study for Monitoring Antimicrobial Resistance Trends (SMART)  by Villegas, Maria Virginia et al.
O
R
IG
IN
A
L 
 
A
R
TI
CL
E
34
Increasing prevalence of extended-spectrum-beta-
lactamase among Gram-negative bacilli in Latin 
America – 2008 update from the Study for Monitoring 
Antimicrobial Resistance Trends (SMART) 
Authors
Maria Virginia Villegas1
Manuel Guzmán Blanco2
Jose Sifuentes-Osornio3
Flávia Rossi4
1MD, MSc, Infectious 
Diseases - International 
Center for Medical 
Research and Training 
(CIDEIM), Cali, Colombia 
2MD, Infectious Diseases - 
Hospital Vargas de Caracas, 
Centro Médico de Caracas, 
Caracas, Venezuela 
3MD, Infectious Diseases 
- National Institute of 
Medical Sciences and 
Nutrition Salvador Zubiran, 
Mexico City, Mexico 
4MD, PhD - Hospital das 
Clínicas da Faculdade de 
Medicina de São Paulo, São 
Paulo, Brasil 
Submitted on: 05/14/2010
Approved on: 06/18/2010
Correspondence to: 
Maria Virginia Villegas
Cra 125 # 
19-225, Cali, Colombia 
Phone: 57-2-5552164
mariavirginia.villegas@
gmail.com
Financial Support: 
Funding for SMART 
was provided by Merck, 
Sharp, & Dohme.
Conﬂ icts of interest:
MVV has received funding 
from Merck, Sharp and 
Dohme; Astra Zeneca; 
Pfi zer; Bayer, Janssen and 
Novartis.
MGB has served on 
advisory boards for Pfi zer; 
Wyeth; Merck, Sharp & 
Dohme; and Biomerieuex. 
He has received research 
grants from International 
Health Management 
Associates, Inc; Janssen; and 
Wyeth. 
JSO has no conﬂ icts of 
interest.
FR was an Advisory Board 
Member for Merck.
ABSTRACT
Objectives: This analysis of the Study for Monitoring Antimicrobial Resistance Trends (SMART) 
evaluated the susceptibility patterns of Enterobacteriaceae in Latin America in 2008, with empha-
sis on susceptibility trends of E. coli and K. pneumoniae. Methods: Clinical isolates were recovered 
from intra-abdominal infections (IAI) from 23 centers in 10 Latin American countries. Isolates were 
sent to a central laboratory for confi rmation of identifi cation, antimicrobial susceptibility and ESBL 
testing, following the Clinical Laboratory Standards Institute (CLSI) guidelines. Results: Of 1,003 
Gram-negative bacilli collected from intra-abdominal infections, E. coli and K. pneumoniae were the 
most commonly isolated organisms, and 26.8% of E. coli and 37.7% of K. pneumoniae were ESBL 
positive. Ertapenem and imipenem were the most consistently active agents tested; 99% of ESBL-
positive E. coli isolates were susceptible to ertapenem and 100% to imipenem as well, and 91% of 
ESBL-positive K. pneumoniae were susceptible to ertapenem and 98% to imipenem. Quinolones and 
cephalosporins were less active, achieving 1.5% to 76% inhibition against ESBL-producing E. coli 
and 3.5% to 61% inhibition against K. pneumoniae. Conclusions: Local and unit-specifi c surveil-
lance data is particularly important for selection of empiric therapy and in community-acquired 
infections as they can help the clinician with antibiotic selection by providing guidance regarding the 
likely pathogens and their resistance profi les. Our data also confi rm the increasing frequency with 
which ESBL-producing organisms are found in the community setting, with 31.4% of community-
acquired and 24.9% of hospital-acquired infections found to produce ESBLs. Imipenem and ertap-
enem are the most active agents tested for ESBL-positive E. coli and K. pneumoniae.
Keywords: carbapenems; beta-lactamases; Gram-negative bacteria; drug resistance; ESBL.
[Braz J Infect Dis 2011;15(1):34-39]©Elsevier Editora Ltda.
INTRODUCTION
Enterobacteriaceae are the most common 
Gram-negative organisms responsible for intra-
abdominal infection (IAI) and Escherichia coli 
is the most frequent pathogen associated with 
IAI.1 While the prevalence of E. coli in diseases 
such as IAI has remained relatively constant, 
its overall susceptibility to antibiotics has de-
creased, as the incidence of extended-spectrum 
beta-lactamase (ESBL) producing isolates has 
increased. ESBL-producing Klebsiella pneumo-
niae has also become a major treatment prob-
lem in IAI.2,3 Antibiotic resistant ESBL-produc-
ing K. pneumoniae has been identifi ed as threats 
to treatment in Latin America, with resistance 
observed in both community- and hospital-
acquired infections.6 In this era of widespread 
resistance among both community and no-
socomial pathogens, improved knowledge of 
local and regional epidemiology and suscep-
tibility patterns is crucial in order to optimize 
empiric antibiotic treatment strategies.4,5 
The Study for Monitoring Antimicrobial Re-
sistance Trends (SMART) is a surveillance study 
that monitors global susceptibility patterns of 
Gram-negative bacteria (GNB) from patients 
hospitalized with IAI.1,7-9 The SMART program 
monitors the activity of amikacin, ampicillin-
sulbactam, cefepime, cefotaxime, cefoxitin, 
ceftazidime, ceftriaxone, ciproﬂ oxacin, ertap-
enem, imipenem, levoﬂ oxacin, and piperacillin-
tazobactam against GNB from IAI. Initiated in 
2002, there were 120 participating SMART cent-
ers worldwide in 2008, with 23 centers in Latin 
America. This sub-analysis of SMART data 
evaluated current susceptibility patterns of En-
terobacteriaceae recovered from IAI in patients 
from Latin America in 2008.
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METHODS
Study sites
In 2008 there were 23 centers in 10 Latin American countries 
that participated in SMART. These centers were located in 
Argentina (2), Brazil (5), Chile (2), Colombia (3), Domini-
can Republic (1), Guatemala (1), Mexico (3), Panama (1), 
Peru (2), and Venezuela (3).
Isolate collection
Up to 100 consecutive non-duplicate clinical isolates were 
collected prospectively from patients with IAI at each center. 
Only the fi rst isolate of a particular species from any patient 
could be included for the entire collection period. Gram-
negative aerobic and facultative bacteria were cultured from 
IAI sites such as appendix, peritoneum, colon, bile, pelvis and 
pancreas. Isolates were obtained during surgery, or through 
paracentesis or percutaneous aspiration of abscesses. Isolates 
from blood, urine, stool, abdominal drains or drainage bot-
tles, superfi cial wounds, and perirectal abscesses were exclud-
ed. Multiple organisms obtained from one specimen were 
acceptable provided each was a unique initial GNB. Isolates 
collected within < 48 hours of hospitalization were catego-
rized as community-acquired and those collected > 48 hours 
after hospitalization were categorized as nosocomial.
Antimicrobial susceptibility testing
Isolates were sent to a central laboratory (Laboratories In-
ternational for Microbiology Studies, a subsidiary of Inter-
national Health Management Associates, Inc., Schaumburg, 
Illinois, USA) for confi rmation of identifi cation and antimi-
crobial susceptibility testing. Susceptibility testing was per-
formed following Clinical Laboratory Standards Institute 
(CLSI) guidelines10 using dehydrated broth microdilution 
panels prepared by MicroScan (Siemens Medical Solutions 
Diagnostics, West Sacramento, California, USA). ESBL test-
ing was done according to CLSI guidelines (CLSI 2009), with 
a positive test requiring at least three doubling dilution de-
crease in minimum inhibitory concentration of ceftazidime or 
cefotaxime in the presence of clavulanic acid. Quality control 
testing was done following CLSI11 and manufacturer (MicroS-
can) guidelines, using reference strains E. coli ATCC 25923, 
E. coli ATCC 35218, Pseudomonas aeruginosa ATCC 27853, and 
K. pneumoniae ATCC 700603. The following antimicrobials, 
obtained from the panel manufacturer, were tested: amikacin, 
ampicillin-sulbactam, cefepime, cefotaxime, cefoxitin, ceftazi-
dime, ceftriaxone, ciproﬂ oxacin, ertapenem, imipenem, levo-
ﬂ oxacin and piperacillin-tazobactam.
RESULTS 
Of the 1,003 GNB isolates collected, 92% were repre-
sented by 9 species: E. coli (n = 504), K. pneumoniae 
(n = 151), Enterobacter cloacae (n = 69), P. aeruginosa (n = 68), 
Proteus mirabilis (n = 37), Citrobacter freundii (n = 24), 
Acinetobacter baumanii (n = 24), Serratia marcescens (n = 23), 
and Enterobacter aerogenes (n = 23). Twenty-two other spe-
cies comprised the remaining 8% of isolates. The most com-
monly isolated organism was E. coli, of which 135 of the isolates 
(26.8%) were ESBL positive. Among the K. pneumoniae iso-
lates, 57 (37.7%) were ESBL positive. Table 1 shows the pro-
portion of ESBL-producing isolates in Latin America. Data for 
the overall Latin American region are described here, with less 
emphasis on country-specifi c data, because the number of iso-
lates collected from each country varied and was in some cases 
too small to be able to discern trends. For example, 86 E. coli 
were collected in Argentina, 83 in Chile, 79 in Venezuela, 61 in 
Guatemala, 43 in Mexico and in Panama, 41 in Brazil, 38 in 
Colombia, 26 in Puerto Rico, and 4 in Dominican Republic.
Antimicrobial susceptibilities of the most commonly iso-
lated pathogens (> 50 isolates) are summarized in Table 2. Sus-
ceptibilities of non-ESBL-producing E. coli, Klebsiella, and Pro-
teus isolates to the carbapenems ranged from 96.8% to 100% 
(ertapenem) and 98.9% to 100% (imipenem). The antimicro-
bial susceptibilities of the ESBL-producing organisms E. coli, K. 
pneumoniae, and K. oxytoca are shown in Figure 1. Among the 
antimicrobials tested, ertapenem and imipenem remained the 
most consistently active against all pathogens, with 99.3% of 
ESBL-producing E. coli and 91.2% of ESBL-producing K. pneu-
moniae susceptible to ertapenem and 100% of ESBL-producing 
E. coli and 98.2% of ESBL-producing K. pneumoniae suscep-
tible to imipenem. All P. mirabilis isolates were susceptible to 
ertapenem and imipenem. Susceptibilities were lower for other 
agents, particularly against ESBL-producing strains. In partic-
ular, ESBL producers appeared to have reduced susceptibility 
to commonly-used antibiotics including cephalosporins, ﬂ uor-
oquinolones, and ampicillin-sulbactam. The susceptibility of 
ESBL-positive E. coli and K. pneumoniae varied somewhat 
by country, although they were most consistently suscepti-
ble to ertapenem and imipenem and least likely to be sus-
ceptible to cefepime or ciproﬂ oxacin. Too few isolates were 
collected to identify defi nitive trends, however. It is worth 
noting that ESBL-producing E. coli (97.8%) and K. pneumoniae 
(100%) were uniformly resistant to ampicillin-sulbactam; non-
ESBL-producing E. coli (51.5%) and K. pneumoniae (40.4%) 
had reduced susceptibility to ampicillin-sulbactam.
Table 1. Frequency of ESBL-positive and ESBL-nega-
tive E. coli and Klebsiella spp. in 2008 in the Latin 
American region
Pathogen             ESBL +             ESBL -
 n % n %
E. coli 135 26.8 369 73.2
K. oxytoca 4 20 16 80
K. pneumoniae 57 37.7 94 62.3
Villegas, Blanco, Sifuentes-Osornio et al.
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100% to imipenem, 88% to amikacin, 6% to cefepime, 22% 
to ciproﬂ oxacin, and 73% to piperacillin/tazobactam. With 
hospital-acquired infections, 99% of ESBL-producing E. 
coli were susceptible to ertapenem, 100% to imipenem, 
85% to piperacillin/tazobactam, 81% to amikacin, 15% to 
ciproﬂ oxacin, 10% to cefepime, and only 2% to ampicillin-
sulbactam. Similarly, 92% and 93% of community- and 
hospital-acquired ESBL-producing K. pneumoniae were 
respectively susceptible to ertapenem and 98% and 100% 
to imipenem, while 74% and 67% of community- and hos-
pital-acquired ESBL-producing K. pneumoniae were sus-
ceptible to amikacin, 12% and 0% to cefepime, 19% and 
33% to ciproﬂ oxacin, and 41% and 50% to piperacillin/
tazobactam, respectively.
DISCUSSION 
The frequency of ESBL-producing E. coli and Klebsiella in 
Latin America was generally higher in 2008 compared with 
that reported from SMART in previous years. Overall, 26% 
of E. coli and 35% of K. pneumoniae isolated from IAI in 
the Latin American region produced ESBLs, compared with 
10% and 14% of E. coli and K. pneumoniae from SMART 
in 2003, and 10% and 18% in 2004.1,7 Other surveillance 
studies have also noted relatively high rates of ESBL-produc-
ing pathogens in Latin America. SENTRY results from Latin 
America (1997-1998) indicated that 46.9% of K. pneumoniae 
strains (n = 1,225) produced ESBLs, with rates ranging from 
26.2% in Venezuela to 52% in Mexico.12 The Tigecycline 
Evaluation and Surveillance Trial (TEST) reported rates of 
ESBL production of 13.5% among E. coli and 44% among 
K. pneumoniae isolates in Latin America (2004-2006).13 
A higher percentage of ESBL-producing Enterobacteriaceae 
were observed in South America than in North America ac-
cording to the Meropenem Yearly Susceptibility Test Infor-
mation Collection (MYSTIC) surveillance study between 
1997 and 2003.14 While 18.1% of E. coli from South Amer-
ica were ESBL positive, only 7.5% of isolates from North 
America were ESBL positive; 51.9% of K. pneumoniae from 
South America were ESBL producers versus 12.3% of North 
American strains.13 In Brazil, 24% of 498 Enterobacteriaceae 
analyzed from 2002 to 2003 were ESBL producers, including 
57% of the K. pneumoniae.15 A similar study in Colombia in 
2002 examined 1,074 E. coli and 394 K. pneumoniae clini-
cal isolates and found a high prevalence of ESBLs in most 
hospitals, among both E. coli (11.8%) and K. pneumoniae 
(32.6%).16 These rates were similar to rates reported in other 
countries in Latin America; some of the hospitals participat-
ing in this study, however, had rates that were substantially 
higher, up to 71.4% for K. pneumoniae and 16.7% for E. coli 
in some intensive care units.16 The rates of ESBL produc-
tion in Latin America appear to be approaching those of the 
Asia/Pacifi c region, where ESBL frequencies of 40% were 
observed in SMART.17
Table 3. Frequency of ESBL-positive and ESBL-negative 
E. coli and Klebsiella spp. in community-acquired and 
hospital-acquired infections in Latin America
Infection Typea           ESBL +           ESBL -  
 n % n %
Community-acquired 
82 26.7 204 71.3
infection
Hospital-acquired 
52 24.4 161 75.6
infection
Not specified 1 20 4 80
Total 135 26.8 369 73.2
aCommunity-acquired infection indicates that the isolate 
was collected within < 48 hours of hospitalization; hospital-
acquired infection indicates that the isolate was collected 
> 48 hours following hospitalization.
Figure 1. Antimicrobial susceptibilities of ESBL-producing 
E. coli and K. pneumoniae in Latin America (2002-2008). 
Susceptibilities are based on in vitro minimum inhibitory 
concentration data.
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Our data also confi rm the increasing frequency with which 
ESBL-producing organisms are found in the community set-
ting, with 31.4% of community-acquired and 24.9% of hospi-
tal-acquired infections found to produce ESBLs. The commu-
nity-acquired rate is similar to that reported in the Asia/Pacifi c 
region (28%) although the rate of hospital-acquired ESBL in-
fection was much higher in the Asia/Pacifi c region (55.4%).17 
In SMART, isolates collected within < 48 hours of hospitali-
zation were categorized as community-acquired and those 
collected > 48 hours after hospitalization were categorized as 
nosocomial, thus it is possible that some cases were miscate-
gorized using these criteria.
Cephalosporins and quinolones susceptibilities of ESBL-
producing organisms in Latin America declined from 2002 
to 2008, while these organisms remained consistently sus-
ceptible to the carbapenems and, for the most part, to ami-
kacin. SENTRY data based on nearly 20,000 community and 
hospital clinical isolates collected in Latin America between 
1997 and 2001, indicated that ESBL-producing E. coli and 
K. pneumoniae remained uniformly susceptible to imipenem 
and meropenem, with high-level resistance to cephalosporins 
(e.g., 48.4% cefepime resistance among K. pneumoniae), 
ﬂ uoroquinolones (e.g., 49.2% levoﬂ oxacin resistance among 
E. coli) and, in some cases, to beta-lactams such as piperacillin/
tazobactam (55.6% resistance among E. coli and 34.3% resist-
ance among K. pneumoniae).18 Imipenem was the most active 
agent against both ESBL-producing E. coli and K. pneumo-
niae in SENTRY and TEST.13,18 Overall susceptibility of ESBL-
producing Klebsiella species reported by SENTRY for 1997 to 
2002 showed resistance rates from 35.8% to 46.9%, although 
rates of ESBL-producing Klebsiella were lower in 2001 to 2002 
(35.8% to 39.5%) compared to 1997 to 2000 (43.5 to 46.9%), 
highlighting yearly variations.19 While ampicillin-sulbactam is 
still commonly used in some Latin American countries, both 
ESBL-producing and non-ESBL-producing E. coli and K. pneu-
moniae were highly resistant. For all of the results in this study, 
it is important to note that susceptibility is defi ned in terms of 
minimum inhibitory concentrations and there is no clinical 
correlation with treatment.
Physicians have relied on the ability of antibiotics to treat in-
fections for many decades. With high-level antibiotic resistance 
manifesting around the world, patients are more likely to be treat-
ed with inadequate antibiotic therapy and consequently more 
likely to die from infections and infectious complications.20-22 
The selection of antibiotic resistant strains due to inappropriate 
antibiotic use and overuse has had a negative impact on hospital 
ecology.23 For example, a retrospective case-control study that in-
cluded all cases of K. pneumoniae bacteremia from a single center 
in Mexico (1993-2002) reported that an ESBL-producing isolate 
was found in 17/121 cases (14%), and that prior cephalosporin 
use (p = 0.039) and previous stay in the intensive care unit 
(p = 0.033) were signifi cant risk factors for infection with ESBL-
producing K. pneumoniae.24
Local and unit-specifi c surveillance data can inform antibi-
otic selection by providing guidance regarding the likely patho-
gens and their resistance profi les. This is particularly important 
for selection of empiric therapy and in community-acquired 
infections where microbiologic data and antibiotic use infor-
mation may not be available. A call for a Latin American sur-
veillance network was made a decade ago to address these con-
cerns.6 The SMART database provides accessible longitudinal 
local, regional, and worldwide data on the susceptibility of iso-
lates from IAI, with the limitations that sites are not uniformly 
distributed and the number of isolates collected at each site 
is variable. Nevertheless, local monitoring of ESBL producer 
prevalence and the susceptibility of these pathogens to com-
monly-used antibiotics is needed to improve patient outcomes 
and preserve the effi cacy of the available antibiotic agents.
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